Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Basilea Pharmaceutica
Deal Size : $72.3 million
Deal Type : Licensing Agreement
Details : Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.
Brand Name : Cresemba
Molecule Type : Small molecule
Upfront Cash : $7.5 million
March 23, 2023
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Basilea Pharmaceutica
Deal Size : $72.3 million
Deal Type : Licensing Agreement
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : VectivBio
Deal Size : Not Applicable
Deal Type : Not Applicable
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 13, 2023
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : VectivBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VEL-101
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : Veloxis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
Brand Name : FR104
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 18, 2022
Lead Product(s) : VEL-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Veloxis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : VectivBio
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Details : The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-hos...
Brand Name : FE203799
Molecule Type : Peptide
Upfront Cash : $30.0 million
March 30, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : VectivBio
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Basilea Pharmaceutica
Deal Size : $72.3 million
Deal Type : Partnership
Details : Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.
Brand Name : Cresemba
Molecule Type : Small molecule
Upfront Cash : $7.5 million
September 30, 2021
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Basilea Pharmaceutica
Deal Size : $72.3 million
Deal Type : Partnership
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Basilea Pharmaceutica
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.
Brand Name : Cresemba
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2021
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Basilea Pharmaceutica
Deal Size : Not Applicable
Deal Type : Not Applicable
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Details : Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.
Brand Name : AK1780
Molecule Type : Undisclosed
Upfront Cash : $20.0 million
January 29, 2021
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Basilea Pharmaceutica
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Brand Name : Cresemba
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 07, 2021
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Basilea Pharmaceutica
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
